Clinical Trial

A Study of Regorafenib Combined With Envafolimab for Metastatic Gastrointestinal Stromal Tumors With Kit Gene Exon 17 Mutation That Failed Standard Treatment

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is a multicenter, prospective, randomized controlled Phase II clinical trial. The primary endpoint is to evaluate the efficacy and safety of regorafenib combined with envafolimab compared to physician's choice in patients with metastatic gastrointestinal stromal tumors harboring KIT exon 17 mutations who have failed standard treatments.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-01-08.
Status change: Recruiting → Not Yet Recruiting 2025-07-28
Trial Details
NCT Number NCT06772233
Lead Sponsor Peking University
Conditions Metastatic Gastrointestinal Stromal Tumors (GIST)
Enrollment 100 participants
Start Date 2025-07-30
Primary Completion 2027-07-30 (estimated)
Study Completion 2028-07-30 (estimated)
Updated on ClinicalTrials.gov 2025-07-31